Recombinant Human MAPK9 protein (His tag)

Recombinant Human MAPK9 protein (His tag)
SKU
ELSPDEH100389-100
Packaging Unit
100 µg
Manufacturer
Elabscience Biotechnology

Availability: loading...
Price is loading...
Abbreviation: MAPK9

Target Synonym: JNK-55;JNK2;JNK2A;JNK2ALPHA;JNK2B;JNK2BETA;p54a;p54aSAPK;PRKM9;SAPK;SAPK1a

Target Species: Human

Expression Host: E.coli

Fusion Tag: N-His & C-His

UNIProt ID: P45984

Background: Mitogen-activated protein kinase 9 (MAPK9), also well known as c-Jun N-terminal kinase (JNK2), is a member of MAP kinase subfamily belonging to the protein kinase superfamily. The crystal structure of human JNK2 complexed with an indazole inhibitor by applying a high-throughput protein engineering and surface-site mutagenesis approach. A novel conformation of the activation loop is observed, which is not compatible with its phosphorylation by upstream kinases. This activation inhibitory conformation of JNK2 is stabilized by the MAP kinase insert that interacts with the activation loop in an induced-fit manner. It suggest that the MAP kinase insert of JNK2 plays a role in the regulation of JNK2 activation, possibly by interacting with intracellular binding partners. JNK2 deficiency leads to reduced c-Jun degradation, thereby augmenting c-Jun levels and cellular proliferation, and suggests that JNK2 is a negative regulator of cellular proliferation in multiple cell types. JNK2 blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells. JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response. Lack of JNK2 expression was associated with higher tumor aneuploidy and reduced DNA damage response. Additionally,the JNK2 protein could be a novel therapeutic target in dry eye disease, and may provide a novel target for prevention of vascular disease and atherosclerosis.

Sequence: Phe 101-Arg 424

Purity: > 95 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Endotoxin: Please contact us for more information.
More Information
SKU ELSPDEH100389-100
Manufacturer Elabscience Biotechnology
Manufacturer SKU ELA-PDEH100389-100
Package Unit 100 µg
Quantity Unit STK
Product information (PDF) Download
MSDS (PDF) Download